We previously reported a family with apolipoprotein C-II (apoC-II) deficiency characterized by the presence of a mutant apoC-il, apoC-llT0r~0t. We now report the purification and primary structure of apoC-IITr..t. The sequence of apoC-llTrOft. is identical to that of normal apoC-il from residues 1-68. It differs from residue 69, where AspGln7O-Val7l-Leu72_Ser73-Val74-Leu75-Lys76-Gly77-Glu78 Glu79 is replaced by Thr69-Lys70-phe7l-Phe72-Leu73-Cys74. This is consistent with the deletion of a nucleotide in the codon for either Thr'8 (9) to allow the isolation of chylomicrons and very low density lipoproteins from 700 ml of plasma in a single run. The Ti 15 rotor was brought to 3000 rpm and loaded sequentially with 700 ml of 0.15 M NaCl (1.006 g/ml), 700 ml of plasma adjusted with KBr to 1.063 g/ml, and 300 ml of 0.15 M NaCl adjusted with KBr to 1.25 g/ml (solution A). The chylomicrons were floated by centrifugation at 20,000 rpm for 1 hr and, after slowing the rotor to 3000 rpm, they were displaced with 60 ml of solution A. The plasma remaining in the rotor was spun at 30,000 rpm for 18 hr, the rotor was slowed to 3000 rpm, and the very low density lipoproteins were displaced with 50 ml of solution A. Chylomicrons and very low density lipoproteins adhering to the rotor core were isolated separately after the rotor had come to a complete stop. Each fraction was dispersed in 0.15 M NaCl/0.01% Na2EDTA/0.02% NaN3 and reisolated by centrifugation in an 80 Ti rotor for 16 hr at 45,000 rpm.
Lipoprotein lipase (LPL; triacylglycero-protein acylhydrolase, EC 3.1.1.34) was first recognized by Hahn (1) as the primary enzyme involved in the lipolysis of plasma triglyceride of chylomicrons and very low density lipoproteins. In 1955, Kom (2) reported that LPL was activated by a factor present in plasma. Apolipoprotein C-II (apoC-II), a major apolipoprotein of chylomicrons and very low density lipoproteins, was subsequently identified as an activator of this enzyme (3, 4) . The discovery in this laboratory of a subject with fasting chylomicronemia caused by a deficiency in apoC-II (5) established the physiological importance of the apolipoprotein as an activator of LPL. This deficiency is inherited as an autosomal recessive trait (6) . We have identified 14 homozygous and 23 obligate heterozygous subjects in the extended pedigree (7) . Their plasma contains a unique apoC-II that has an apparent pI of 5 .54 instead of 4 .88 as in normal apoC-II. It was identified as a mutant apoC-II by immunoblot analysis with an antiserum specific for apoC-II (8) . In this publication, we describe the purification and the primary structure of this mutant apoC-II, which we designate apoC-IIToronto (apoC-IIT).
METHODS
Purification of apoC-UT. Lipemic plasma (2.1 liters) was collected by plasmapheresis from an apoC-IIT homozygous patient (6) . The plasma triglyceride level was 33.8 mmol/liter and total cholesterol level was 7.2 mmol/liter. The chylomicrons and the very low density lipoproteins were isolated by ultracentrifugation in a zonal Ti 15 rotor (Beckman). We modified the method of Wilcox et al. (9) to allow the isolation of chylomicrons and very low density lipoproteins from 700 ml of plasma in a single run. The Ti 15 rotor was brought to 3000 rpm and loaded sequentially with 700 ml of 0.15 M NaCl (1.006 g/ml), 700 ml of plasma adjusted with KBr to 1.063 g/ml, and 300 ml of 0.15 M NaCl adjusted with KBr to 1.25 g/ml (solution A). The chylomicrons were floated by centrifugation at 20,000 rpm for 1 hr and, after slowing the rotor to 3000 rpm, they were displaced with 60 ml of solution A. The plasma remaining in the rotor was spun at 30,000 rpm for 18 hr, the rotor was slowed to 3000 rpm, and the very low density lipoproteins were displaced with 50 ml of solution A. Chylomicrons and very low density lipoproteins adhering to the rotor core were isolated separately after the rotor had come to a complete stop. Each fraction was dispersed in 0.15 M NaCl/0.01% Na2EDTA/0.02% NaN3 and reisolated by centrifugation in an 80 Ti rotor for 16 hr at 45,000 rpm.
The C apolipoproteins were isolated from these fractions by treatment with acetone (10, 11) . The lyophilized protein was delipidated with ethanol/diethylether (11) . The analysis of this acetone-soluble product by analytical polyacrylamide isoelectric focusing using a pH 4-6.5 gradient showed it to contain apoC-IIT and the isomorphs of apolipoprotein C-IIIi.e., C-III-0, C-III-1, and C-III-2 (8) .
ApoC-IIT was purified to homogeneity by a single preparative flat-bed isoelectric focusing step using Ultradex granulated gel and pH [4] [5] [6] (12) . The gel containing apoC-IIT was removed and eluted first with 1 ml and then with 2.5 ml of 0.5% NaDecSO4/0.01 M Tris HCl, pH 8.2. The combined eluates were mixed with ice-cold acetone (9 vol of acetone to 1 vol of eluate) and allowed to stand at 4°C for 10 min. The precipitated protein was pelleted by centrifugation at 2000 rpm for 20 min. The precipitate was washed twice with 10 ml of ice-cold acetone. The viscous oil-like residue present was extracted with 5 ml of chloroform/methanol (2:1) at room temperature to produce a white powder. ApoC-IIT was identified by analytical isoelectric focusing and shown to be homogeneous (8) . Normal apoC-II was isolated from a control subject following the identical protocol.
Amino Acid Analysis. Approximately 10-,ug duplicate aliquots of apoC-II and apoC-IIT were hydrolyzed with 6 M HCO at 110°C for 20 hr. The amino acid compositions were determined by using a Beckman 120C amino acid analyzer and standard elution conditions (13) .
Derivatization of Cysteine. Fifty to 100 ,ug of chylomicron apolipoprotein or very low density lipoprotein apolipoprotein and their fractions were dissolved in 100 ,ul of 0.1 M NH4HCO3, pH 8.0/0.2% NaDecSO4/20 mM dithiothreitol, and incubated at 37°C for 30 min. Sodium iodoacetate (0.5 M, pH 8.0) was then added to a final concentration of 0.1 M and the samples were incubated at room temperature for an additional 30 min. The samples were then evaluated for the incorporation of a negative charge by analytical isoelectric focusing (8, 14) .
Abbreviations: apoC-II, apolipoprotein C-II; apoC-IIT, apolipoprotein C-IIToronto; LPL, lipoprotein lipase; NaDecSO4, decyl sodium sulfate.
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The cysteine residue of apoC-IIT was also derivatized with 4-vinylpyridine (15) . Fifty milligrams of acetone-soluble apolipoprotein was dissolved in 3 ml of 10 (16) .
Further information on the sequence was obtained from tryptic peptides after separation by reverse-phase HPLC. The profile of the tryptic peptides of apoC-IIT was compared with that of normal apoC-II (Fig. 1) . Six major peaks were identified in the profiles of both apolipoproteins. The retention times of the first five peaks of each profile are the same within experimental error, suggesting that these fragments are the same in apoC-II and apoC-IIT. The retention time of the sixth peak in the two profiles differs, suggesting that this contains the site of a mutation. The amino acid composition of each peak was determined after acid hydrolysis. Peaks P1-P6 of normal apoC-II and P1'-P5' of apoC-IIT were identified as tryptic peptides predicted from the sequence of normal apoC-II (Fig. 1) . The composition of P6' did not correspond to any tryptic fragment of normal apoC-II.
To identify the cysteine-containing peptide of apoC-IIT, 50 mg of acetone-soluble protein was reduced and treated with tCysteine was shown to be present by the method of Creighton (14) . 4-vinylpyridine (15) . Pyridylethylated apoC-IIT was isolated by preparative isoelectric focusing and digested with trypsin. The tryptic peptides were separated by reverse-phase HPLC. The pyridylethyl cysteine-containing peptide was identified as P7' by its strong absorption at 254 nm and 280 nm (Fig. 1) .
The amino acid sequences of the peptides in peaks 6' and 7' as determined in an Applied Biosystems 470A sequenator are shown in Fig. 2 . Each of these peptides was completely sequenced, including the COOH-terminal residues. Peptide P6' consisted of 15 residues, of which the first 13 were identical with residues 56-68 of normal apoC-II. However, Asp6-Gln70 of normal apoC-II was replaced by Thr69-Lys70. Inspection of the DNA sequence of the apoC-II gene (17) indicated that this could arise from a deletion of either a thymidine nucleotide from the codon for Thr' or a guanine nucleotide from the codon for Asp69. The subsequent reading frame-shift predicts the sequence Phe71-Phe72-Leu73-Cys74 for the COOH-terminal residues of apoC-IIT. This is in agreement with the observation that apoC-IIT contains a cysteine residue and is confirmed by the sequence Phe-PheLeu-(pyridylethyl)Cys for peptide P7'. Seven different families have been reported with an apoC-II deficiency since the description of the family investigated here (7, (18) (19) (20) (21) (22) (23) . The subjects from Padova have been reported to have traces of a mutant form of apoC-II in their plasma (24) that is different from apoC-IIT as shown by twodimensional electrophoresis and immunoblot analysis.
We have established the exact nature of the mutation that resulted in the production of a nonfunctional apoC-II in the Toronto subjects. It is interesting to note that whereas deletion of a base prior to the codon for Met6 would result in a stop codon at this point, the deletion of any single base between the thymidine of the codon for Met6O and the first guanine of the codon for Val74 would result in frame-shift mutants that would have a COOH-terminal cysteine residue.
The importance of apoC-IIT is that it is nonfunctional in spite of being only five amino acid residues shorter than the normal protein. Its lack offunction may be due to the absence of residues 69-79 or it may be the result of the properties of the mutant portion 69-74. The function of normal apoC-II has been studied through the use of peptide fragments and synthetic peptides (25) . On been deduced that the LPL activation domain consists of residues 56-67 and contains a serine residue essential to the function of apoC-II (26) . Peptides containing both the LPL activation and the lipid binding domains activate LPL as effectively as whole apoC-II. These sequences are intact in apoC-IIT. It has further been postulated, on the basis of the predicted A-sheet conformation (25) , that residues 65-75 constitute a LPL binding domain. The sequence of apoC-IIT is significantly different from apoC-II in this region, although the algorithm of Chou and Fasman (27) predicts that residues 65-74 of apoC-IIT are also in a p-sheet conformation. Two possibilities can account for the loss of function of apoC-IIT. Either all three domains, including residues 69-79, are required for the proper function of apoC-II in vivo or the change from the sequence Asp-Gln-Val-Leu-Ser-Val of normal apoC-II to the more hydrophobic sequence Thr-LysPhe-Phe-Leu-Cys generates a new lipid binding domain. This would alter the orientation of the activation domain relative to the LPL molecule and render it inactive. We favor the latter possibility.
